Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor vs Clopidogrel in High Ischemic Risk Post-PCI Patients
NCT04989257Phase 4Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Aug 2021
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ticagrelor in coronary artery disease (CAD) and myocardial infarction (MI) (2 arms), sponsored by Yonsei University. Primary endpoint: Composite of all-cause death, myocardial infarction, or stroke at 24 months. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
ticagrelor
03
Conditions
coronary artery disease (CAD)myocardial infarction (MI)
Beyond the preview
Go deeper on NCT04989257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04989257.